Treatment continuum
Inhalants rehab.
Treatment for inhalant use disorder — volatile solvents, aerosols, nitrites, anesthetic gases. Inhalant use is uncommon in adults but carries unique medical risks including sudden sniffing death, neurological damage, and organ injury that require informed clinical management.
Overview
Inhalants rehab is the structured, professionally supervised treatment of inhalant use disorder across the full continuum of care. Inhalants are a diverse category — volatile solvents (gasoline, paint thinner, glue, correction fluid), aerosols (spray paint, hair spray, computer dusters), nitrites (commonly called poppers), and anesthetic gases (nitrous oxide, ether) — that share the route of administration but differ substantially in clinical risk profile. Inhalant use is most prevalent among adolescents and is comparatively uncommon in adults presenting for treatment, but adult inhalant use disorder is a serious clinical condition that carries unique medical risks: sudden sniffing death syndrome (cardiac arrhythmia in the absence of warning), neurological damage from chronic solvent exposure, organ injury (liver, kidney, lung), and developmental neurotoxicity in younger users. SILC Health operates licensed inhalant use disorder treatment programs in California and Georgia, accepts most major commercial insurance, and integrates medical screening for organ damage with residential addiction treatment and structured continuing care.
Medically reviewed by Peter Scheid, MD
Medical Director, SILC Health
Clinically reviewed by Alexandra Truman, LMFT
Clinical Director, Substance Use Services — SILC Health
Last reviewed: June 16, 2026
Section 1
What this is.
Inhalant use disorder is a DSM-5 diagnosis covering compulsive use of volatile solvents, aerosols, nitrites, or anesthetic gases despite functional impairment. The diagnostic criteria parallel other substance use disorders, but the clinical picture differs in important ways: there is no recognized inhalant withdrawal syndrome of the kind seen with alcohol, benzodiazepines, or opioids; the acute risk profile (sudden sniffing death, hypoxia, accidental injury) is unusually severe for the population that uses; and chronic use produces a distinctive pattern of neurological and organ damage that informs the clinical workup.
The inhalants category is heterogeneous. Volatile solvents (toluene, butane, halogenated hydrocarbons) act primarily through GABAergic and glutamatergic mechanisms similar to alcohol and produce a short-lived disinhibited intoxication. Nitrites (amyl nitrite, isobutyl nitrite, alkyl nitrites) act through vasodilation and are most commonly used in sexual contexts. Anesthetic gases (nitrous oxide in particular) act through NMDA antagonism and can produce profound dissociative effects. Each carries its own pattern of acute and chronic harm; clinical treatment is informed by which inhalant the client primarily uses.
Inhalant rehab is most often appropriate for clients with daily or near-daily inhalant use producing functional impairment, polysubstance use involving inhalants and other substances, co-occurring mental health conditions, evidence of neurological or organ damage that warrants medical management, or environments where structured 24-hour separation from inhalant access is necessary. Medical workup at admission typically includes neurological examination, cognitive screening, liver and kidney function, complete blood count, and (when indicated) brain imaging for clients with chronic heavy solvent use.
Sudden sniffing death
Sudden sniffing death syndrome — cardiac arrhythmia and death without warning — can occur with any inhalant use, including a first use. The risk is highest with halogenated hydrocarbon solvents (computer duster, refrigerants) and is not dose-dependent.
Neurotoxicity
Chronic inhalant use, particularly of toluene-containing solvents, produces a distinctive pattern of neurological damage: cognitive impairment, cerebellar dysfunction (ataxia, tremor), peripheral neuropathy, and white matter changes visible on MRI.
Section 2
The continuum of care.
1. Medical detox (5–10 days, ASAM Level 3.7)
Inhalant detox at SILC is medically managed with 24/7 nursing and physician oversight. Withdrawal symptoms are managed pharmacologically; vitals and cognitive status are monitored continuously; complications are escalated immediately. Detox is the foundation — the work that follows is harder without it. See more →
2. Residential treatment (30 / 60 / 90+ days, ASAM Level 3.1–3.5)
Residential — sometimes called "inpatient" — is the longest and most intensive phase. Clients live on-site, participate in structured clinical programming daily, attend individual and group therapy, work with family when appropriate, build recovery skills, and stabilize physically and emotionally. Length of stay is clinically determined; most clients with moderate-to-severe substance use disorder benefit from at least 60 days.
3. Partial Hospitalization (PHP) — day treatment (ASAM Level 2.5)
PHP is the first step down from 24-hour residential care. Clients spend most of the day in clinical programming (typically 5–6 days per week, 5–6 hours per day) but return to sober living or stable housing each night. PHP supports reintegration into community life while still providing intensive clinical structure.
4. Intensive Outpatient (IOP) — 9–15 hours weekly (ASAM Level 2.1)
IOP runs 9–15 hours per week across 3 days, allowing return to work, school, or family responsibilities. Clinical focus shifts toward relapse prevention, ongoing therapy, and community reintegration. IOP often runs in parallel with recovery fellowship participation.
5. Outpatient + aftercare (indefinite)
Standard outpatient — individual therapy, psychiatric medication management when indicated, group therapy with a community provider — extends after IOP and continues indefinitely. Aftercare also includes recovery fellowship participation, sober living when appropriate, and ongoing alumni programming.
Section 3
Who this is for.
Inhalant use disorder is treated under the DSM-5 framework with severity graded by criteria met. Inhalant use is most prevalent among adolescents and is comparatively uncommon in adults presenting for residential treatment; adult cases that do present often involve polysubstance use, severe co-occurring psychiatric conditions, or workplace exposures that progressed to chronic use.
Residential inhalants rehab is clearly indicated for: daily or near-daily inhalant use, polysubstance use involving inhalants and other substances, co-occurring mental health conditions complicating outpatient management, evidence of neurological damage (cognitive impairment, peripheral neuropathy, cerebellar dysfunction) that warrants medical management and longer-stay residential structure, organ damage requiring monitoring, or environments where structured 24-hour separation from inhalant access is necessary.
There is no recognized inhalant withdrawal syndrome of the kind seen with alcohol, benzodiazepines, or opioids — formal medical detox is not typically required for inhalants alone. However, polysubstance presentations involving inhalants frequently do require ASAM Level 3.7 medical detox for the other substances involved.
Section 4
A day in residential.
Residential inhalant rehab is structured but not regimented. Most days at a SILC facility follow a clinical rhythm designed to balance therapeutic work, peer connection, physical wellness, and rest.
- •Morning: Wake, vitals check during detox phase, mindfulness or meditation, breakfast, community meeting.
- •Mid-morning to lunch: Individual therapy session or process group; psychiatric or medical check-ins when relevant.
- •Afternoon: Skill-building group (CBT, DBT, relapse prevention), or experiential work (movement, art, equine therapy depending on facility), or family session when scheduled.
- •Late afternoon: Physical wellness (exercise, beach walk at coastal California facilities, fitness room), peer time, dinner.
- •Evening: Recovery fellowship meeting (AA, SMART, or alternative), reflection group, journaling, rest.
Family communication is supported per the client's preference. Family programming — visits, family therapy sessions, and structured education on supporting recovery — is clinically encouraged once initial stabilization is complete, typically after the first 5–10 days.
DSM-5 diagnosis
Inhalant use disorder is a recognized DSM-5 diagnosis with severity grades from mild to severe, paralleling other substance use disorders.
Polysubstance pattern
Adult inhalant use disorder presentations frequently involve polysubstance use. SILC's clinical workup screens for concurrent alcohol, benzodiazepine, opioid, and stimulant use disorder as standard practice.
Section 5
Insurance + cost.
Most major commercial insurance plans cover residential treatment at SILC facilities, including Aetna, Anthem Blue Cross / BCBS plans, Blue Shield of California, Cigna, UnitedHealthcare, Surest, MultiPlan / PHCS, ConnectiCare, Oxford / Harvard Pilgrim, NYSHIP (Empire Plan), Empire BCBS, and Prairie States Enterprises. Network status with any given carrier varies by SILC facility and the patient's specific plan.
Out-of-state insurance is commonly accepted under most plans' out-of-state benefit provisions — Empire BCBS (NY), BCBS Texas, BCBS Florida, Aetna nationwide plans, and UnitedHealthcare nationwide plans typically cover treatment at SILC California facilities.
The SILC admissions team verifies your specific benefits, in plain language, before any clinical commitment. Most insured clients pay a manageable share after coverage; private-pay and financing options are available for clients without insurance or whose plans don't cover residential treatment at the clinically indicated level.
See all accepted insurance carriers →Section 6
Where SILC operates.
SILC Health operates licensed substance use treatment programs in two regions: coastal California (San Diego County) and North Georgia (Towns County). Medical detox is available at Cove Detox (Carlsbad), Leucadia Detox (Encinitas), Seaside Detox (Oceanside), Harbor Detox (Dana Point), and Riverfront Recovery Center (Hiawassee, GA). Residential addiction treatment is anchored by Southern California Recovery Centers (Carlsbad) and Riverfront Recovery Center (Hiawassee, GA).
Roughly two-thirds of SILC's California admissions originate from outside California — the climate, the recovery community, the distance from triggers at home, and the depth of California's continuing-care ecosystem are the most common reasons families choose to travel here for treatment. The Riverfront catchment skews more regional — drive-distance from Tennessee, Kentucky, Indiana, and surrounding states.
See all SILC facilities →Related
Dig deeper.
First step
Inhalants Detox
Medical management of inhalants withdrawal — timeline, medications, and what to expect.
The diagnosis
Inhalants rehab
Clinical overview, signs and symptoms, and how this condition is diagnosed.
The setting
Residential Treatment
What residential treatment looks like — daily schedule, therapies, length of stay.
Coverage
Insurance Verification
How SILC verifies your benefits — including out-of-state coverage.
The process
What to Expect
From the first phone call through arrival at the facility — step by step.
Co-occurring
Dual Diagnosis
Treating substance use and mental health conditions together.
FAQ
Frequently asked questions.
- What counts as an inhalant?
- Inhalants are a diverse category covering volatile solvents (gasoline, paint thinner, glue, correction fluid, computer duster), aerosols (spray paint, hair spray, deodorants), nitrites (amyl nitrite, isobutyl nitrite, alkyl nitrites — commonly called poppers), and anesthetic gases (nitrous oxide, ether). They share the inhalation route of administration but differ substantially in mechanism, risk profile, and clinical management.
- Do inhalants cause withdrawal?
- There is no recognized inhalant withdrawal syndrome of the kind seen with alcohol, benzodiazepines, or opioids. Formal medical detox is not typically required for inhalants alone. Some heavy users report mild discomfort, irritability, and craving on cessation, but the syndrome is not medically dangerous. Polysubstance presentations involving inhalants frequently do require medical detox for the other substances involved.
- What is sudden sniffing death syndrome?
- Sudden sniffing death syndrome is cardiac arrhythmia leading to death without warning, associated with inhalant use. It can occur with any inhalant — including a first use — and is highest-risk with halogenated hydrocarbon solvents (computer duster, refrigerants). The risk is not dose-dependent. This is one reason inhalant use carries such a serious acute risk profile despite the absence of a withdrawal syndrome.
- What kind of medical workup does inhalants rehab include?
- Medical workup at admission typically includes neurological examination, cognitive screening, liver and kidney function, complete blood count, and — when clinically indicated by chronic heavy solvent use — brain imaging to evaluate for white matter changes. Clients with cerebellar signs, peripheral neuropathy, or cognitive impairment may receive longer residential stays to allow for neurological recovery and adaptive intervention.
- Can the neurological damage from chronic inhalant use recover?
- Recovery is variable. Some neurological effects of chronic solvent use — cognitive impairment, peripheral neuropathy — show meaningful recovery with sustained abstinence over months to years. Other effects, particularly significant white matter changes from heavy toluene exposure, may be partially or permanently irreversible. Early intervention substantially improves the recovery picture.
- How long is residential inhalants rehab?
- Length of stay is clinically determined by ASAM criteria and is influenced by neurological status and co-occurring conditions. Clients with significant cognitive impairment or other neurological signs typically benefit from longer residential stays (30–60+ days) to allow for recovery and adaptive intervention. Polysubstance presentations require longer stays still.
- What therapies are used in inhalants rehab?
- Evidence-based modalities include Cognitive Behavioral Therapy (CBT), Motivational Interviewing, contingency management, family systems therapy, and trauma-informed care. Cognitive remediation approaches may be added for clients with measurable cognitive impairment. No FDA-approved medication is available specifically for inhalant use disorder.
- Does SILC treat inhalant use with co-occurring conditions?
- Yes. Inhalant use disorder co-occurs frequently with other substance use disorders, depression, anxiety, PTSD, ADHD, and conduct disorder (particularly in adolescent and young adult presentations). SILC's integrated dual-diagnosis programs treat both presentations concurrently with psychiatric care, psychotherapy, and medication management.
- Does SILC accept insurance for inhalants rehab?
- Most major commercial plans cover inhalant use disorder treatment at SILC at multiple levels of care, including Aetna, Anthem Blue Cross / BCBS, Blue Shield, Cigna, UnitedHealthcare, Surest, MultiPlan / PHCS, ConnectiCare, Oxford / Harvard Pilgrim, NYSHIP, Empire BCBS, and Prairie States Enterprises. SILC verifies benefits in plain language during the admissions conversation.
- What happens after inhalants rehab ends?
- Continuing care includes outpatient programming (PHP, then IOP, then standard outpatient), individual therapy, recovery fellowship participation (NA, SMART, or alternatives), ongoing psychiatric care for co-occurring conditions, neurological follow-up when indicated, and family support. SILC coordinates direct handoff with home-state providers including written discharge summary, clinical notes (with client authorization), and warm introductions to outpatient teams.
Talk to admissions
Recovery starts with a call.
One call confirms benefits, walks through what arrival looks like, and sets a clear plan from detox through aftercare.